|
市場調査レポート
商品コード
1403564
自動セルカウンティングの世界市場規模、シェア、産業動向分析レポート:製品別、用途別、最終用途別、地域別展望と予測、2023年~2030年Global Automated Cell Counting Market Size, Share & Industry Trends Analysis Report By Product, By Application (Cell Line development, Blood Analysis, Stem Cell Research, and Others), By End-use, By Regional Outlook and Forecast, 2023 - 2030 |
||||||
自動セルカウンティングの世界市場規模、シェア、産業動向分析レポート:製品別、用途別、最終用途別、地域別展望と予測、2023年~2030年 |
出版日: 2023年12月28日
発行: KBV Research
ページ情報: 英文 310 Pages
納期: 即納可能
|
自動セルカウンティング市場規模は2030年までに86億米ドルに達すると予測され、予測期間中のCAGRは12.2%の市場成長率で上昇します。
KBV Cardinalのマトリックスに示された分析によると、F. Hoffmann-La Roche Ltd.が同市場におけるトップランナーです。2021年12月、F. Hoffmann-La Roche Ltd.は3つの新しい自動デジタル病理アルゴリズム、uPath Ki-67(30-9)、uPath PR(1E2)、uPath ER(SP1)の乳がん画像解析の発売を発表しました。このアルゴリズムは、病理医が乳がんマーカーを定量化する際に役立つ、病理医による評価前のスライド画像の自動事前計算により、スライド解析ワークフロー全体を容易にします。Thermo Fisher Scientific社、Abbott Laboratories社、Danaher Corporation社などは、この市場における主要なイノベーターです。
COVID-19影響分析
パンデミックの間、研究努力と資源はSARS-CoV-2ウイルスの理解、診断テストの開発、ワクチン開発に大きく振り向けられました。この研究の優先順位の一時的なシフトは、他の分野での自動セルカウンティングアプリケーションなど、COVIDに関連しない研究の一部地域での減速につながった。パンデミックは世界のサプライチェーンを混乱させ、機械式細胞計数装置や関連消耗品の生産、流通、入手に影響を与えました。製造の遅れ、出荷の制約、物流の課題は一時的に市場の成長に影響を与えました。したがって、COVID-19パンデミックは市場に中程度の影響を与えました。
市場成長要因
研究開発に対する政府支出の増加
細胞生物学、再生医療、および関連分野における科学的発見、技術革新、治療法の開発を進める上で、細胞ベースの研究に対する政府予算の増加は極めて重要です。資金提供の増加により、科学者は細胞メカニズム、シグナル伝達経路、様々なタイプの細胞の挙動をより深く理解することができます。この基礎知識は、慢性疾患に対する標的療法や介入策を開発するための基礎となります。再生医療、組織工学、疾患モデリングにおける幹細胞の可能性を追求することで、新たな治療法や臓器再生への道が開かれます。このように、研究開発における政府資金の増加は市場の成長を促進しています。
細胞ベースの食品に対する需要の高まり
細胞ベースの家畜、乳製品、卵、その他の製品の生産を包含する細胞農業の領域が拡大していることは、自動セルカウンティング装置に新しいアプリケーションを提示しています。細胞の増殖と培養は、細心の監視が必要な製造プロセスの不可欠な要素です。食品バイオ製造施設向けの適正製造基準(GMP)に準拠した自動計数器ソリューションを開発する企業は、このニッチ分野で価値を獲得することができます。細胞農業企業への投資や提携は、長期的拡大の機会をもたらす可能性があります。このように、細胞ベースの食品の動向の高まりが市場の成長を後押ししています。
市場抑制要因
専門オペレーターとトレーニングの必要性
高度な自動セルカウンターを効率的に操作・維持するには、熟練したスタッフと技術的知識が必要です。予算やリソースの制約に阻まれている多くの検査室は、専門的なトレーニングを提供しなければならないです。システムの潜在能力を完全に活用できる有能な人材の不足が、制約要素となっています。看護学校や医科大学などのヘルスケア教育プログラムの能力不足は、この分野に参入する有能な専門家の数を制限しています。したがって、訓練を受けた熟練した人材の不足が市場の成長を妨げています。
製品の展望
製品によって、市場は器具と消耗品・付属品に二分されます。消耗品・付属品セグメントは2022年の市場で最も高い収益シェアを獲得しました。フローサイトメーター、イメージベースセルカウンター、血液学アナライザーのような自動セルカウンティング機器の採用が増えるにつれて、これらの機器に関連する消耗品やアクセサリーのニーズも高まっています。同市場における消耗品やアクセサリーの需要増加は、細胞分析技術の応用拡大や標準化・品質管理の必要性と密接に関連しています。
装置の展望
装置セグメントは、フローサイトメーター、画像ベースセルカウンター、電気インピーダンスカウターカウンターに細分化されます。2022年には、フローサイトメーターセグメントが市場で注目すべき収益シェアを獲得しました。これらの装置は、細胞のハイスループットとマルチパラメトリック分析を提供し、研究者、臨床医、製薬会社が細胞機能、疾病メカニズム、治療開発についてより深い洞察を得ることを可能にします。技術の進歩、アプリケーションの拡大、精密で包括的な細胞解析のニーズの高まりが、フローサイトメーターの需要拡大に寄与しています。
用途展望
用途別に見ると、市場は血液分析、幹細胞研究、細胞株開発、その他に区分されます。2022年には、血液分析セグメントが市場で注目すべき収益シェアを獲得しました。血液分析は臨床診断の基本です。血液分析に対する需要の増加は、正確でタイムリーな診断の必要性、技術の進歩、個別化医療への注目、さまざまなヘルスケア環境における血液検査の重要な役割によってもたらされ、疾病管理、治療、研究の要となっています。
最終用途の展望
市場は最終用途に基づき、製薬・バイオテクノロジー企業、病院・診断研究所、研究・学術機関、その他に分類されます。製薬&バイオテクノロジー企業セグメントは、2022年の市場で最も高い収益シェアを示しました。複数の製薬会社やバイオテクノロジー会社が、自動セルカウンティング装置の製造業者として、あるいは研究、医薬品開発、製造プロセスにこの技術を活用するユーザーとして、市場で重要な役割を果たしています。
地域別展望
地域別に見ると、市場は北米、欧州、アジア太平洋、LAMEAで分析されます。北米地域は、2022年の同市場において最大の収益シェアを占めています。北米は市場で重要な位置を占めています。シリコンバレーやボストン、サンフランシスコのクラスターのような地域は、自動セルカウンティングの技術進歩を推進する数多くのバイオテクノロジー企業や研究機関の本拠地です。ライフサイエンス、バイオテクノロジー、ヘルスケアの研究開発に対する政府からの旺盛な資金援助が細胞計数技術の進歩を支えています。
The Global Automated Cell Counting Market size is expected to reach $8.6 billion by 2030, rising at a market growth of 12.2% CAGR during the forecast period.
Image-based cell counters offer high accuracy and precision in cell counting and analysis. Therefore, the Image-based Cell Counters segment captured $424.4 million revenue in the market in 2022. These systems use advanced imaging technology and algorithms to capture and analyze cell images, providing detailed information about cell morphology, viability, and concentration. As research methodologies become more advanced and diverse, the demand for accurate and efficient cell counting solutions, particularly those based on imaging technology, is expected to grow.
The major strategies followed by the market participants are Product Launches as the key developmental strategy to keep pace with the changing demands of end users. For instance, In September, 2022, Thermo Fisher Scientific, Inc. released the DynaSpin Single-Use Centrifuge system. The system is specifically meant for large-scale cell culture harvesting and aids the users in reducing overall production. Additionally, In October, 2021, Sysmex Corporation unveiled XN-30 Automated Haematology Analyzer for malaria detection. The XN-30 leverages a combination of specialized reagents, advanced algorithms, and violet laser to differentiate P. falciparum from non-falciparum species and find out the life cycle staging of the parasites detected.
Based on the Analysis presented in the KBV Cardinal matrix; F. Hoffmann-La Roche Ltd. are the forerunners in the market. In December, 2021, F. Hoffmann-La Roche Ltd announced the launch of three new automated digital pathology algorithms, uPath Ki-67 (30-9), uPath PR (1E2), and uPath ER (SP1) image analysis for breast cancer. The algorithms facilitate the whole slide analysis workflow with automated pre-computing of the slide image before pathologist assessment which aids the pathologists in quantification of the breast cancer markers. Companies such as Thermo Fisher Scientific, Inc., Abbott Laboratories and Danaher Corporation are some of the key innovators in the market.
COVID-19 Impact Analysis
During the pandemic, research efforts and resources were significantly redirected toward understanding the SARS-CoV-2 virus, developing diagnostic tests, and developing vaccines. This temporary shift in research priorities led to a slowdown in some regions of non-COVID-related research, including automated cell counting applications in other fields. The pandemic disrupted global supply chains, affecting the production, distribution, and availability of mechanical cell counting instruments and related consumables. Delays in manufacturing, shipping constraints, and logistical challenges temporarily impacted the market's growth. Therefore, the COVID-19 pandemic moderately impacted the market.
Market Growth Factors
Growing government expenditure for R&D
Increasing government funding for cell-based research is crucial in advancing scientific discoveries, technological innovations, and therapeutic developments in cell biology, regenerative medicine, and related areas. Increased funding allows scientists to delve deeper into understanding cellular mechanisms, signalling pathways, and the behaviour of various cell types. This fundamental knowledge forms the basis for developing targeted therapies and interventions for chronic diseases. Funding aids in exploring the potential of stem cells in regenerative medicine, tissue engineering, and disease modelling, paving the way for novel treatments and organ regeneration. Thus, the increasing government funding in research and development is driving the growth of the market.
Rising demand for cell-based food products
The growing domain of cellular agriculture, which encompasses the production of cell-based livestock, dairy, eggs, and other products, presents novel applications for automated cell counting instruments. Cell proliferation and culture constitute an integral component of the manufacturing process that necessitates meticulous oversight. Value can be captured in this niche by firms that develop good manufacturing practice (GMP) compliant automated counter solutions for food biomanufacturing facilities. Investments and partnerships with cellular agriculture firms may present opportunities for long-term expansion. Thus, the increasing trend of cell-based food is propelling the growth of the market.
Market Restraining Factors
Requirement for specialized operators and training
Proficient staff and technical knowledge are necessary to operate and maintain sophisticated automated cell counters effectively, particularly those that rely on images. Numerous laboratories hindered by budgetary and resource constraints must provide specialized training. The insufficiency of competent personnel capable of harnessing the complete potential of the systems constitutes a constraining element. Insufficient capacity in healthcare education programs, such as nursing schools and medical colleges, limits the number of qualified professionals entering the field. Hence, a scarcity of trained and skilful personnel is impeding the growth of the market.
Product Outlook
Based on product, the market is bifurcated into instruments and consumables & accessories. The consumables and accessories segment garnered the highest revenue share in the market in 2022. As the adoption of automated cell counting instruments like flow cytometers, image-based cell counters, and haematology analysers rises, so does the need for consumables and accessories associated with these instruments. The increasing demand for consumables and accessories in the market is closely linked to the expanding applications of cell analysis technologies and the need for standardization and quality control.
Instruments Outlook
The instruments segment is subdivided into flow cytometers, image-based cell counters, and electrical impedance coulter counters. In 2022, the flow cytometers segment procured a noteworthy revenue share in the market. These instruments provide high throughput and multiparametric analysis of cells, enabling researchers, clinicians, and pharmaceutical companies to gain deeper insights into cellular functions, disease mechanisms, and therapeutic developments. Technological advancements, expanding applications, and the increasing need for precise and comprehensive cell analysis contribute to the rising demand for flow cytometers.
Application Outlook
On the basis of application, the market is segmented into blood analysis, stem cell research, cell line development, and others. In 2022, the blood analysis segment attained a noteworthy revenue share in the market. Blood analysis is a fundamental aspect of clinical diagnostics. The increasing demand for blood analysis is driven by the need for accurate and timely diagnosis, technological advancements, a focus on personalized medicine, and the crucial role of blood testing in various healthcare settings, making it a cornerstone in disease management, treatment, and research.
End-Use Outlook
Based on the end-use, the market is categorized into pharmaceutical & biotechnology companies, hospitals & diagnostic laboratories, research & academic institutes, and others. The pharmaceutical & biotechnology companies segment witnessed the highest revenue share in the market in 2022. Several pharmaceutical and biotechnological companies play significant roles in the market, either as manufacturers of automated cell counting instruments or as users leveraging this technology for their research, drug development, and manufacturing processes.
Regional Outlook
Region-wise, the market is analysed across North America, Europe, Asia Pacific, and LAMEA. The North America region witnessed the maximum revenue share in the market in 2022. North America holds a significant position in the market. Regions like Silicon Valley and clusters in Boston and San Francisco are home to numerous biotech firms and research institutions driving technological advancements in automated cell counting. Robust government funding for research and development in life sciences, biotechnology, and healthcare supports advancements in cell counting technology.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Shanghai Ruiyu Biotechnology Co., Ltd. (Alit Biotech (Shanghai) Co., Ltd.), Thermo Fisher Scientific, Inc., Bio-Rad laboratories, Inc., F. Hoffmann-La Roche Ltd., Danaher Corporation, Olympus Corporation, Merck KGaA, Abbott Laboratories, Sysmex Corporation, and Agilent Technologies, Inc.
Recent Strategies Deployed in Automated Cell Counting Market
Product Launches and Product Expansions:
Sep-2022: Thermo Fisher Scientific, Inc. released the DynaSpin Single-Use Centrifuge system. The system is specifically meant for large-scale cell culture harvesting and aids the users in reducing overall production.
Dec-2021: F. Hoffmann-La Roche Ltd announced the launch of three new automated digital pathology algorithms, uPath Ki-67 (30-9), uPath PR (1E2), and uPath ER (SP1) image analysis for breast cancer. The algorithms facilitate the whole slide analysis workflow with automated pre-computing of the slide image before pathologist assessment which aids the pathologists in quantification of the breast cancer markers.
Oct-2021: Sysmex Corporation unveiled XN-30 Automated Hematology Analyzer for malaria detection. The XN-30 leverages a combination of specialized reagents, advanced algorithms, and violet laser to differentiate P. falciparum from non-falciparum species and find out the life cycle staging of the parasites detected.
Sep-2021: Merck KGaA introduced ProCellics Raman Analyzer, a cell culture analyzer. The system uses Bio4C PAT Raman software and delivers in-line and real-time cell culture monitoring.
Dec-2020: Merck KGaA announced the launch of the Scepter 3.0 handheld automated cell counter. The device delivers error-free cell counting by using a combination of analog and digital hardware for sensing, signal processing, data storage, and graphical display. Additionally, it contains a laser-drilled aperture in its cell-sensing zone.
Jan-2020: Olympus Corporation released the Provi CM20 monitoring system, a cell culture monitoring system. The system scans the cultures, and the number of cells and determines confluency on a periodical basis.
Partnerships, Collaborations & Agreements:
Oct-2023: F. Hoffmann-La Roche Ltd signed a partnership with Ibex Medical Analytics, an Israeli biotechnology company, to integrate its Navify Digital Pathology software platform with Ibex's AI-powered decision support tools. Through the partnership, Navify Digital Pathology platform pathologists would be able to securely access third-party AI-powered technology alongside Roche's growing menu of AI-based image analysis tools in an efficient clinical workflow.
Jun-2023: OGT, a subsidiary of Sysmex Corporation, announced a partnership with Applied Spectral Imaging (ASI), an advanced biomedical imaging solutions provider. Under the partnership, OGT would gain the marketing rights for ASI's proprietary cytogenetic imaging and analysis solutions. The partnership would enable clinical laboratories to strengthen their comprehensive genomic structural measurement capabilities.
Feb-2023: Thermo Fisher Scientific, Inc. came into partnership with Celltrio, a Cell Culture automation solutions provider, to develop a fully automated cell culture system for biotherapeutic applications. The solutions that would be developed in the course of the partnership would facilitate the users to deliver innovative therapies to patients by leveraging effective scale processing.
Aug-2020: Thermo Fisher Scientific, Inc. entered a partnership with FCS Express, a flow cytometry software offered by De Novo Software, to integrate its FCS Express software capability with its Invitrogen Attune NxT acoustic flow cytometer system. The combination of the two products would allow the customers to easily compare results across samples and produce publication-quality graphics at the time of instrument installation.
Mergers & Acquisition:
Feb-2021: Thermo Fisher Scientific, Inc. took over cell sorting technology assets from Propel Labs, a cell sorting solutions provider. The acquisition complements and strengthens Thermo Fisher's flow cytometry offering.
Trials and Approvals:
Aug-2023: Abbott Laboratories received approval from the US FDA for its Alinity h-series hematology system. The approval allows Abbott to strengthen its diagnostics business.
Market Segments covered in the Report:
By Product
By Application
By End-use
By Geography
Companies Profiled
Unique Offerings from KBV Research